AR069769A1 - Tratamiento del melanoma con peptidos de timosina alfa en combinacion con un inhibidor de quinasas - Google Patents
Tratamiento del melanoma con peptidos de timosina alfa en combinacion con un inhibidor de quinasasInfo
- Publication number
- AR069769A1 AR069769A1 ARP080105451A ARP080105451A AR069769A1 AR 069769 A1 AR069769 A1 AR 069769A1 AR P080105451 A ARP080105451 A AR P080105451A AR P080105451 A ARP080105451 A AR P080105451A AR 069769 A1 AR069769 A1 AR 069769A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- melanoma
- alpha
- kinase inhibitor
- treatment
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 239000002295 alkylating antineoplastic agent Substances 0.000 abstract 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 2
- 108010046075 Thymosin Proteins 0.000 abstract 2
- 238000011269 treatment regimen Methods 0.000 abstract 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 108010078233 Thymalfasin Proteins 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 229960003787 sorafenib Drugs 0.000 abstract 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1347607P | 2007-12-13 | 2007-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069769A1 true AR069769A1 (es) | 2010-02-17 |
Family
ID=40755899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105451A AR069769A1 (es) | 2007-12-13 | 2008-12-15 | Tratamiento del melanoma con peptidos de timosina alfa en combinacion con un inhibidor de quinasas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100267637A1 (enExample) |
| EP (1) | EP2240194A4 (enExample) |
| JP (1) | JP2011506473A (enExample) |
| CN (1) | CN101945664A (enExample) |
| AR (1) | AR069769A1 (enExample) |
| AU (1) | AU2008335025A1 (enExample) |
| CA (1) | CA2708229A1 (enExample) |
| WO (1) | WO2009076587A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943101A1 (en) * | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604845A1 (de) * | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| EP2633866A3 (en) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
| US20070292392A1 (en) * | 2006-06-15 | 2007-12-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
-
2008
- 2008-12-12 CN CN2008801268138A patent/CN101945664A/zh active Pending
- 2008-12-12 AU AU2008335025A patent/AU2008335025A1/en not_active Abandoned
- 2008-12-12 JP JP2010538181A patent/JP2011506473A/ja active Pending
- 2008-12-12 US US12/747,438 patent/US20100267637A1/en not_active Abandoned
- 2008-12-12 WO PCT/US2008/086545 patent/WO2009076587A1/en not_active Ceased
- 2008-12-12 EP EP08858909A patent/EP2240194A4/en not_active Withdrawn
- 2008-12-12 CA CA2708229A patent/CA2708229A1/en not_active Abandoned
- 2008-12-15 AR ARP080105451A patent/AR069769A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2708229A1 (en) | 2009-06-18 |
| JP2011506473A (ja) | 2011-03-03 |
| US20100267637A1 (en) | 2010-10-21 |
| EP2240194A4 (en) | 2011-12-21 |
| CN101945664A (zh) | 2011-01-12 |
| AU2008335025A1 (en) | 2009-06-18 |
| EP2240194A1 (en) | 2010-10-20 |
| WO2009076587A1 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| CO6361942A2 (es) | Terapia de combinacion con epoxicetonas peptidicas | |
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| AR074203A1 (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso. | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| CO2018006358A2 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2010009447A (es) | Uso de antagonistas de lhrh a dosis no castrantes. | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| AR074603A1 (es) | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit | |
| NI201200085A (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| AR069682A1 (es) | Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) | |
| UY29274A1 (es) | Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida | |
| AR069767A1 (es) | Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa) | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| ES2563068T3 (es) | Tratamiento de esclerosis múltiple (MS) con Campath-1H | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| UY31826A (es) | Compuesto peptídico y su uso | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| AR069769A1 (es) | Tratamiento del melanoma con peptidos de timosina alfa en combinacion con un inhibidor de quinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |